669 related articles for article (PubMed ID: 16097847)
1. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.
Schubiner H
CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847
[TBL] [Abstract][Full Text] [Related]
2. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
Kollins SH
Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
[TBL] [Abstract][Full Text] [Related]
3. Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations.
Klassen LJ; Bilkey TS; Katzman MA; Chokka P
Curr Drug Abuse Rev; 2012 Sep; 5(3):190-8. PubMed ID: 22571450
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.
Pérez de los Cobos J; Siñol N; Pérez V; Trujols J
Br J Clin Pharmacol; 2014 Feb; 77(2):337-56. PubMed ID: 23216449
[TBL] [Abstract][Full Text] [Related]
5. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
Upadhyaya HP
J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
[TBL] [Abstract][Full Text] [Related]
6. Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders.
Simon N; Rolland B; Karila L
Curr Pharm Des; 2015; 21(23):3359-66. PubMed ID: 26088112
[TBL] [Abstract][Full Text] [Related]
7. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder].
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Z Kinder Jugendpsychiatr Psychother; 2021 Jan; 50(1):54-67. PubMed ID: 34397296
[TBL] [Abstract][Full Text] [Related]
8. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study.
Dalsgaard S; Mortensen PB; Frydenberg M; Thomsen PH
Addict Behav; 2014 Jan; 39(1):325-8. PubMed ID: 24090624
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
Goldman LS; Genel M; Bezman RJ; Slanetz PJ
JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
[TBL] [Abstract][Full Text] [Related]
10. Attention-deficit/hyperactivity disorder and early-onset substance use disorders.
Wilson JJ; Levin FR
J Child Adolesc Psychopharmacol; 2005 Oct; 15(5):751-63. PubMed ID: 16262592
[TBL] [Abstract][Full Text] [Related]
11. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder.
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Eur Addict Res; 2020; 26(4-5):223-232. PubMed ID: 32634814
[TBL] [Abstract][Full Text] [Related]
12. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.
Molina BS; Hinshaw SP; Eugene Arnold L; Swanson JM; Pelham WE; Hechtman L; Hoza B; Epstein JN; Wigal T; Abikoff HB; Greenhill LL; Jensen PS; Wells KC; Vitiello B; Gibbons RD; Howard A; Houck PR; Hur K; Lu B; Marcus S;
J Am Acad Child Adolesc Psychiatry; 2013 Mar; 52(3):250-63. PubMed ID: 23452682
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and treatment of patients with comorbid substance use disorder and adult attention-deficit and hyperactivity disorder: a review of recent publications.
van der Burg D; Crunelle CL; Matthys F; van den Brink W
Curr Opin Psychiatry; 2019 Jul; 32(4):300-306. PubMed ID: 31008730
[TBL] [Abstract][Full Text] [Related]
14. International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.
Crunelle CL; van den Brink W; Moggi F; Konstenius M; Franck J; Levin FR; van de Glind G; Demetrovics Z; Coetzee C; Luderer M; Schellekens A; ; Matthys F
Eur Addict Res; 2018; 24(1):43-51. PubMed ID: 29510390
[TBL] [Abstract][Full Text] [Related]
15. Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders.
Skoglund C; Brandt L; D'Onofrio B; Larsson H; Franck J
Eur Neuropsychopharmacol; 2017 Nov; 27(11):1144-1152. PubMed ID: 28935267
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence.
Cunill R; Castells X; Tobias A; Capellà D
J Psychopharmacol; 2015 Jan; 29(1):15-23. PubMed ID: 25142405
[TBL] [Abstract][Full Text] [Related]
17. [Adolescents with concurrent ADHD and substance use disorder; international consensus].
Spijkerman R; Crunelle CL; Özgen MH; Begeman AHA; Dom G; van de Glind G; Groenman AP; van Kernebeek MW; Matthys F; Post M; Schellekens A; Staal W; van den Brink W; Hendriks VM
Tijdschr Psychiatr; 2021; 63(12):868-874. PubMed ID: 34978058
[TBL] [Abstract][Full Text] [Related]
18. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
19. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.
Perugi G; Vannucchi G
Expert Opin Pharmacother; 2015; 16(14):2193-204. PubMed ID: 26364896
[TBL] [Abstract][Full Text] [Related]
20. Attention deficit/hyperactivity disorders with co-existing substance use disorder is characterized by early antisocial behaviour and poor cognitive skills.
Bihlar Muld B; Jokinen J; Bölte S; Hirvikoski T
BMC Psychiatry; 2013 Dec; 13():336. PubMed ID: 24330331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
